Home » Stocks » KNSA

Kiniksa Pharmaceuticals Ltd. (KNSA)

Stock Price: $19.72 USD -0.05 (-0.25%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Market Cap 1.34B
Revenue (ttm) n/a
Net Income (ttm) -139.52M
Shares Out 65.96M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $19.72
Previous Close $19.77
Change ($) -0.05
Change (%) -0.25%
Day's Open 20.06
Day's Range 19.06 - 20.48
Day's Volume 422,836
52-Week Range 11.00 - 26.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on M...

GlobeNewsWire - 1 month ago

- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab –

GlobeNewsWire - 1 month ago

– Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously – – Evaluating vixarelimab across a range of once-monthly dose regimens injected subcutaneously –

GlobeNewsWire - 1 month ago

- R eceptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous –

GlobeNewsWire - 2 months ago

HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on T...

GlobeNewsWire - 2 months ago

- PDUFA goal date of March 21, 2021 - - Filing based on positive data from RHAPSODY , which achieved its primary  and all major secondary endpoints - - Rilonacept BLA for CAPS transferred to K...

GlobeNewsWire - 2 months ago

Primary and secondary efficacy endpoints achieved statistical significance; mavrilimumab reduced risk of flare and increased sustained remission Primary and secondary efficacy endpoints achiev...

GlobeNewsWire - 2 months ago

HAMILTON, Bermuda, Nov. 05, 2020 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immun...

GlobeNewsWire - 2 months ago

Kiniksa expects to initiate a dose-ranging Phase 2b clinical trial of vixarelimab in prurigo nodularis in the fourth quarter of 2020 Kiniksa expects to initiate a dose-ranging Phase 2b clinica...

GlobeNewsWire - 3 months ago

- Mavrilimumab r educe d t ime - to - f lare and i ncrease d s ustained r emission in Phase 2 giant cell arteritis clinical t rial - - Primary and secondary efficacy endpoints achieved statist...

GlobeNewsWire - 3 months ago

- Primary and secondary efficacy endpoints statistically significant - - Primary and secondary efficacy endpoints statistically significant -

GlobeNewsWire - 4 months ago

- Virtual e vent to take place from 8:00 a.m. to 9: 3 0 a.m. E D T -

GlobeNewsWire - 4 months ago

- Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT- - Virtual event scheduled for Monday, September 28th, 2020 from 8:00 a.m. to 9:30 a.m. EDT-

GlobeNewsWire - 4 months ago

HAMILTON, Bermuda , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Morgan Stanley 18th Annual Global Healthcare...

GlobeNewsWire - 4 months ago

HAMILTON, Bermuda, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

GlobeNewsWire - 5 months ago

HAMILTON, Bermuda, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on ...

GlobeNewsWire - 5 months ago

– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year –

GlobeNewsWire - 6 months ago

HAMILTON, Bermuda, July 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381...

GlobeNewsWire - 6 months ago

HAMILTON, Bermuda, July 20, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of $100...

GlobeNewsWire - 6 months ago

HAMILTON, Bermuda, July 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

Benzinga - 6 months ago

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares were trading higher Monday after the company's Phase 3 trial of Rilonacept showed statistically significant results.

Zacks Investment Research - 6 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: EXPI, ICLK, LAKE, VIVO
GlobeNewsWire - 6 months ago

HAMILTON, Bermuda, June 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and c...

Zacks Investment Research - 7 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: CALX, EXPI, ICLK, STKL
Seeking Alpha - 7 months ago

Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 7 months ago

HAMILTON, Bermuda, June 08, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and c...

GlobeNewsWire - 7 months ago

HAMILTON, Bermuda, May 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and co...

Zacks Investment Research - 8 months ago

Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

HAMILTON, Bermuda, May 18, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 ...

GlobeNewsWire - 8 months ago

HAMILTON, Bermuda, May 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 2,400,000 ...

GlobeNewsWire - 8 months ago

– Mavrilimumab treatment protocol in patients with severe COVID-19 pneumonia and hyperinflammation showed improved clinical outcomes compared to matched contemporaneous controls, including ear...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals

GlobeNewsWire - 9 months ago

- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 - - Statistically significant secondary efficacy endpo...

Seeking Alpha - 9 months ago

Kiniksa announced an unexpected move into the COVID-19 furore.

Zacks Investment Research - 9 months ago

Is (KNSA) Outperforming Other Medical Stocks This Year?

24/7 Wall Street - 9 months ago

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: AVRO, FATE, MRSN, NVCR, ORTX, SYBX, TCRR
GlobeNewsWire - 9 months ago

  - All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation; follow-on controlled study in Italy planned -  - Consortium of U.S. aca...

GlobeNewsWire - 9 months ago

- Phase 2 study data show the potential for rilonacept treatment to eliminate or reduce the risk of corticosteroid-associated morbidity in recurrent pericarditis - - Enrollment complete for ...

The Motley Fool - 11 months ago

These three clinical-stage biotechs could all double in value before year's end.

Other stocks mentioned: ADAP, APLT
GlobeNewsWire - 1 year ago

Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta

GlobeNewsWire - 1 year ago

HAMILTON, Bermuda, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that Sanj K. Patel, Chief Executive Officer and Chairman of the Board of K...

The Motley Fool - 1 year ago

A much-needed vote of confidence lifted an entire industry.

Other stocks mentioned: CGC, PAYC
GlobeNewsWire - 1 year ago

HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference ...

The Motley Fool - 1 year ago

The company's lead drug candidate earned Breakthrough Therapy designation from American regulators.

24/7 Wall Street - 1 year ago

Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for ri...

GlobeNewsWire - 1 year ago

HAMILTON, Bermuda, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

GlobeNewsWire - 1 year ago

– Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 – – Operating plan funded into 2H 2021; no current plan to raise additional capital prior ...

The Motley Fool - 1 year ago

Some investors think the market's been too hard on these drugmakers.

Other stocks mentioned: GTHX, REGN
Zacks Investment Research - 1 year ago

Kiniksa Pharmaceuticals, Ltd. (KNSA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GlobeNewsWire - 1 year ago

Data reinforce the scientific evidence supporting the potential treatment of chronic pruritic diseases through OSMRβ inhibition Data reinforce the scientific evidence supporting the potential ...

About KNSA

Kiniksa Pharmaceuticals,, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis... [Read more...]

Industry
Biotechnology
IPO Date
May 24, 2018
CEO
Sanj K. Patel
Employees
135
Stock Exchange
NASDAQ
Ticker Symbol
KNSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is 34.00, which is an increase of 72.41% from the latest price.

Price Target
$34.00
(72.41% upside)
Analyst Consensus: Strong Buy